Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNNI3K | Q59H18 | 15/20 | 0.55 |
| ▸ | BRAF | P15056 | 1/20 | 0.44 |
| ▸ | CDK4 | P11802 | 2/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14322805 | 0.91 | TNNI3K (0.49) | TNNI3KEGFRERBB3 | |
| SCHEMBL14323497 | 0.91 | BRAF (0.56) | TNNI3KBRAFCDK4CDK2EGFR | |
| SCHEMBL14322490 | 0.87 | TNNI3K (0.68) | TNNI3KBRAF | |
| SCHEMBL14323546 | 0.85 | BRAF (0.45) | TNNI3KBRAFCDK4CDK2 | |
| Trifluoroacetic Acid SCHEMBL14323472 | 0.83 | TNNI3K (0.67) | TNNI3KBRAFEGFR | |
| SCHEMBL14323387 | 0.82 | TNNI3K (0.61) | TNNI3KCDK4CDK2EGFRERBB3 | |
| SCHEMBL12517511 | 0.82 | TNNI3K (0.73) | TNNI3KBRAFEGFR | |
| SCHEMBL14323482 | 0.80 | TNNI3K (0.58) | TNNI3KBRAF | |
| SCHEMBL14323710 | 0.79 | TNNI3K (0.63) | TNNI3KBRAF | |
| SCHEMBL14323797 | 0.79 | TNNI3K (0.62) | TNNI3KBRAFEGFRERBB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120329784-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC | 2012-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329784-A1 | COMPOUNDS AND METHODS | RB1, DHFR, NQO1 | TNNI3K 2596/4885BRAF 1164/4885CDK4 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.